Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma

Targeting tumor-associated blood vessels to increase immune infiltration may enhance treatment effectiveness, yet limited data exist regarding anti-angiogenesis effects on the tumor microenvironment (TME). We hypothesized that dual targeting of angiogenesis with immune checkpoints would improve both...

Full description

Bibliographic Details
Main Authors:	Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2023-04-01
Series:	JCI Insight
Subjects:	Oncology
Online Access:	https://doi.org/10.1172/jci.insight.157347

Similar Items

1070 ‘Decoy-resistant’ IL-18 in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
by: Lin Zhang, et al.
Published: (2023-11-01)

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
by: Dijana Djureinovic, et al.
Published: (2023-11-01)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
by: Ronen Stoff, et al.
Published: (2023-05-01)

830 Inhibition of macrophage migration inhibitory factor (MIF) to overcome immune checkpoint resistance in melanoma
by: Lin Zhang, et al.
Published: (2023-11-01)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
by: Gaurav Sharma, et al.
Published: (2022-10-01)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
by: Gaurav Sharma, et al.
Published: (2020-09-01)

Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
by: Ruth Halaban, et al.
Published: (2024-03-01)

Anti-PD-1 Therapy-Associated Perforating Colitis
by: Romulo Celli, et al.
Published: (2018-01-01)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
by: William Damsky, et al.
Published: (2019-06-01)

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy
by: Zhong-Chen Li, et al.
Published: (2024-03-01)

Efficacy and safety of anti-PD-1 monotherapy anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
by: Qingyan Liu, et al.
Published: (2023-10-01)

Evaluation of the antitumor activity of moronecidin (Piscidin)-like peptide in combination with anti-PD-1 antibody against melanoma tumor
by: Mohsen Mohammadi, et al.
Published: (2023-09-01)

1437 Proteomic profiling of tumor microenvironment in desmoplastic melanoma using the nanostring geomx digital spatial profiler
by: Harriet Kluger, et al.
Published: (2023-11-01)

CAPability‐01: Success of anti‐PD‐1, HDAC inhibitor, and anti‐VEGF combination in colorectal cancer
by: Yujie Tan, et al.
Published: (2024-09-01)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01)

Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report
by: Can Chen, et al.
Published: (2020-09-01)

Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer
by: David Buka, et al.
Published: (2019-01-01)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
by: Paolo A. Ascierto, et al.
Published: (2015-02-01)

A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy
by: Jia-Li Zhao, et al.
Published: (2022-10-01)

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
by: Magdalena K. Zielińska, et al.
Published: (2025-02-01)

Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?
by: Alvise Sernicola, et al.
Published: (2022-10-01)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
by: Bart Neyns, et al.
Published: (2022-07-01)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
by: Long Yang, et al.
Published: (2023-09-01)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
by: Grant R Williams, et al.
Published: (2020-10-01)

849 Snail mucus increases the anti-cancer activity of anti-PD-L1 antibody in melanoma
by: Wei-Chien Huang, et al.
Published: (2023-11-01)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
by: Jani Huuhtanen, et al.
Published: (2023-03-01)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
by: Deirdre Kelly, et al.
Published: (2021-01-01)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
by: Wu JY, et al.
Published: (2021-10-01)

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
by: Nathalie Labarrière, et al.
Published: (2020-05-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
by: Jie Mei, et al.
Published: (2021-02-01)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
by: Xiaopei Cui, et al.
Published: (2021-12-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
by: Muhammad Zubair Afzal, et al.
Published: (2018-02-01)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
by: Wei Wei, et al.
Published: (2023-08-01)

MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
by: Pei-Jung Lee, et al.
Published: (2024-12-01)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
by: Bert H O'Neil, et al.
Published: (2017-01-01)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
by: Priyanka B. Subrahmanyam, et al.
Published: (2018-03-01)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
by: Lin Liu, et al.
Published: (2020-10-01)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
by: Guilan Shi, et al.
Published: (2022-11-01)